6533b825fe1ef96bd128338f

RESEARCH PRODUCT

Improving mRNA-Based Therapeutic Gene Delivery by Expression-Augmenting 3' UTRs Identified by Cellular Library Screening.

Valesca BukurMartin LöwerAndreas KuhnLena M. KranzOrlandini Von Niessen AlexandraMarco PoleganovCorina RechnerTim BeissertBritta VallazzaMustafa DikenStephanie FesserUgur SahinArianne PlaschkeÖZlem Türeci

subject

Untranslated regionCellular differentiationRNA StabilityInduced Pluripotent Stem CellsBlood DonorsComputational biologyGene deliveryBiologyCancer Vaccines03 medical and health sciencesMice0302 clinical medicineDrug DiscoveryGeneticsCoding regionAnimalsHumansRNA MessengerInduced pluripotent stem cellMolecular BiologyGene3' Untranslated RegionsCells Cultured030304 developmental biologyGene LibraryPharmacology0303 health sciencesMessenger RNAMice Inbred BALB CVaccinationGene Transfer TechniquesGenetic TherapyFibroblastsCellular Reprogramming030220 oncology & carcinogenesisMolecular MedicineFemaleOriginal ArticleReprogrammingHalf-Life

description

Synthetic mRNA has emerged as a powerful tool for the transfer of genetic information, and it is being explored for a variety of therapeutic applications. Many of these applications require prolonged intracellular persistence of mRNA to improve bioavailability of the encoded protein. mRNA molecules are intrinsically unstable and their intracellular kinetics depend on the UTRs embracing the coding sequence, in particular the 3′ UTR elements. We describe here a novel and generally applicable cell-based selection process for the identification of 3′ UTRs that augment the expression of proteins encoded by synthetic mRNA. Moreover, we show, for two applications of mRNA therapeutics, namely, (1) the delivery of vaccine antigens in order to mount T cell immune responses and (2) the introduction of reprogramming factors into differentiated cells in order to induce pluripotency, that mRNAs tagged with the 3′ UTR elements discovered in this study outperform those with commonly used 3′ UTRs. This approach further leverages the utility of mRNA as a gene therapy drug format.

10.1016/j.ymthe.2018.12.011https://pubmed.ncbi.nlm.nih.gov/30638957